Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2020-05-12 Regulatory Filings
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings
2020-05-12 English
10-Q
Interim / Quarterly Report Q1 2020
2020-05-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 7, 2020, reporting the issuance of a press release regarding financial results for the first quarter ended March 31, 2020. It references a press release (Exhibit 99.1) and mentions a conference call to review financial results. The document itself is short (3770 characters) and primarily serves to announce the earnings release and related conference call, rather than containing detailed financial statements or substantive financial data. According to the MENU VS MEAL RULE, such a document is an Earnings Release (ER) announcement rather than the full report. Therefore, the appropriate classification is Earnings Release (ER).
2020-05-07 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-05-04 English
DEF 14A
Proxy Solicitation & Information Statement
2020-04-28 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of common stock and warrants. It includes detailed terms of the offering, pricing, use of proceeds, risk factors, and legal disclaimers. The document is a registration statement supplement and prospectus, which is a disclosure document used in capital raising activities. It is not a financial report, earnings release, or management discussion. The presence of offering price, placement agent fees, and details about the securities offered clearly indicate this is a capital/financing update. Therefore, the document fits the category of Capital/Financing Update (CAP).
2020-04-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.